Navigation Links
Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
Date:9/13/2011

/">www.clinicaltrials.gov.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in five Phase 2b trials, including abbreviated duration interferon and interferon-free regimens, in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice: +1 (609) 865-0693Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be s
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Announces Two-for-One Forward Stock Split
2. Pharmasset to Present at Canaccord Genuity Growth Conference
3. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
4. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
7. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
8. Pharmasset to Webcast an Investor Event From the EASL Meeting
9. Pharmasset to Present at Three Upcoming Investor Conferences
10. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
11. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... 26 Reportlinker.com announces that a new market ... Reportlinker Adds Medical Devices & Equipment ... http://www.reportlinker.com/p0156603/Reportlinker-Adds-Medical-Devices--Equipment-in-India-(2009).html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... new lifestyles has made healthcare services in India ...
... The American College of ... Annual Scientific Meeting, becoming the first medical association to expand into ... Meeting attendees, authors and presenters can, for the first time, not ... clinical gastroenterology during -- and well after -- the San Diego ...
Cached Medicine Technology:Reportlinker Adds Medical Devices & Equipment in India (2009) 2Reportlinker Adds Medical Devices & Equipment in India (2009) 3Reportlinker Adds Medical Devices & Equipment in India (2009) 4Reportlinker Adds Medical Devices & Equipment in India (2009) 5Reportlinker Adds Medical Devices & Equipment in India (2009) 6American College of Gastroenterology to Revolutionize Scientific Exchange on Within3 2American College of Gastroenterology to Revolutionize Scientific Exchange on Within3 3
(Date:4/17/2014)... as the leading weapon against the deadly disease could ... research indicating it simply needs to be administered differently. ... cheap anti-malarial drug chloroquine in treating and preventing the ... half a million people each year around the world. ... to chloroquine, but research carried out at the Australian ...
(Date:4/16/2014)... 15, 2014 The Translational Genomics Research Institute (TGen) ... Founders Dinner for their support of TGen,s research into ... March 28 in Scottsdale. , Catherine Ivy, Founder and ... TGen,s John S. McCain Leadership Award, named for U.S. ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... fish caused nearly half of all injuries aboard commercial ... freezer-longliner vessels operating off the coast of Alaska, new ... those injuries and others aboard the two types of ... the research methods used in the study could help ...
(Date:4/15/2014)... the University of California, San Diego School of Medicine have ... C virus get liver disease and why the virus is ... , The hard-to-kill pathogen, which infects an estimated 200 million ... mitochondria dismantling the cell,s innate ability to fight infection. ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Breaking bad mitochondria 2
... before marriage, say an overwhelming 91 percent in an SMS ... ,The survey, conducted by manoramaonline/yuva, saw 22,578 people ... was a must before marriage. Just 2,032 said that such ... just been published. ,According to the Kerala State ...
... and less inclined to follow a career in general practice, ... of Australia.// ,Dr Catherine Joyce, Senior Lecturer in ... and co-author of the study, says places in the general ... of the past six years. ,The study compared ...
... Org" is currently touring South Africa to raise awareness of ... ,Betty Chiu, a member of this organization has ... encouraging other youngsters to follow her example and get themselves ... Org' was established three years ago at a Canadian high ...
... links exist between Alzheimer's and Type 2 diabetes, which has ... forms of the same disease. ,Researchers have found ... is similar to the effect of Alzheimer's on the brain. ... International Conference on Alzheimer's Disease and Related Disorders in Madrid, ...
... investigators from the Howard Hughes Medical Institute, have developed ... unknown genetic mutations that can trigger cancerous growth. The ... analyse the proteins instead of the genes, which are ... reduced the time it takes to target the molecular ...
... clinic has been established by two leading fertility experts, ... ages of 45 with the// treatment. ,Professor ... leading authority in the field of IVF, and Paul ... to carry out pre-implantation genetic diagnosis that is the ...
Cached Medicine News:Health News:Majority of Keralites Vote in Favor of HIV Certificate Before Marriage 2Health News:Diabetes and Alzheimer's disease May be Two Sides of the Same Coin 2Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 2Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 3Health News:Scotland's First 'Stand-Alone' Private Fertility Centre Established 2Health News:Scotland's First 'Stand-Alone' Private Fertility Centre Established 3Health News:Scotland's First 'Stand-Alone' Private Fertility Centre Established 4
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Plate Reader is an eight channel photometer for the sequential and simultaneous reading of micro-plate strips with 96 wells. High technology, user friendly, powerful and reliable....
TC-98 elisa strip reader. Reads, calculates, and prints results for up to 12 wells in about 30 seconds. Single point calibration. Multi-point calibration....
Stat Fax 2200 Incubator shaker....
Medicine Products: